Status:
COMPLETED
Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
Chronic hepatitis C is a liver disease related to a virus: hepatitis C virus (HCV). The type of HCV present in Egypt (genotype 4), has the reputation to respond poorly to Interferon treatment at the c...
Detailed Description
Egypt is the country with the highest HCV prevalence worldwide, and the number of infected Egyptians is estimated around 8 million. The HCV genotype circulating in Egypt is genotype 4. This genotype h...
Eligibility Criteria
Inclusion
- HCV antibodies using a third generation test
- HCV RNA positive by PCR
- Liver biopsy in the past 18 months with METAVIR score over A2 and over or equal to F1, or over or equal A1 and over F2
- ALT over 1.5 time the normal range in the 24 weeks prior to inclusion (Week-28; W-2);
- Patients never treated with ribavirin, IFNalpha or PEG-IFNalpha
- Normal albumin
- Prothrombin time over or equal to 60 percent
- Normal bilirubin
- Alpha-foeto-protein under or equal to 3 times the normal range for the laboratory
- HBs antigen negative
- Two negative Kato test (for S.mansoni) three days apart
- Hemoglobin over or equal 11g/dl,
- Leucocytes over or equal 3000/mm3
- Neutrophils over or equal 1500/mm3
- Platelets over or equal 100 000/mm3
- Blood creatinin over or equal 150 micromol/l
- Normal TSH
- Anti-nuclear antibodies under 1/160
- Fasting blood sugar between 70-115mg/dl (if glucose intolerance or diabetes: HbA1C \<= 8,5%)
- Normal ophthalmologic examination in patients with history of blood pressure and/or diabetes
- Effective contraception during the treatment period
- No breastfeeding during the study period.
- Signed informed consent
Exclusion
- Co-infection with hepatitis B (positive HBs antigen)
- Hemochromatosis
- Alpha-1 anti-trypsin deficiency
- Wilson disease
- Alcoholism-related liver disease
- Gilbert disease
- Alcohol intake over 50g/day for males and 40 g/day for females
- Ongoing intravenous drug use
- Aggravated liver cirrhosis (history or presence of ascitis, oesophageal varicosis, liver encephalopathy)
- Hepatocellular carcinoma
- Psychiatric disease: history of severe nervous breakdown or severe psychiatric diseases such as major psychosis, suicidal ideas, suicide attempts…
- Epilepsy
- Auto-immune disease
- Heart disease in the six months preceding enrolment - patients with significant changes at EKG
- Uncontrolled diabetes
- Chronic respiratory insufficiency with hypoxemia \<10 kPa
- Medical or surgical condition, non-stabilised, with life expectancy lower than two years.
- Pregnancy or breastfeeding
Key Trial Info
Start Date :
August 1 2002
Trial Type :
INTERVENTIONAL
End Date :
January 1 2005
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00158496
Start Date
August 1 2002
End Date
January 1 2005
Last Update
April 24 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Ismail Sallam hospital
Zawiat Razin, Menoufia, Egypt
2
National Hepatology and Tropical Medicine Research Institute
Cairo, Egypt